BCR-ABL by PCR Quantitative

BCR-ABL BY PCR QUANTITATIVE Test Purpose

The BCR-ABL by PCR Quantitative Test is a highly sensitive molecular test that measures the amount of BCR-ABL fusion gene transcripts in the blood or bone marrow. The BCR-ABL fusion gene is formed due to a genetic change known as the Philadelphia chromosome, which results from the exchange of genetic material between chromosomes 9 and 22. This abnormal gene produces an overactive protein that causes uncontrolled growth of white blood cells.

Healthcare providers commonly recommend this test for the diagnosis and long-term monitoring of Chronic Myeloid Leukemia (CML). It is also used in selected cases of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). Unlike qualitative testing, the quantitative PCR test measures the exact level of BCR-ABL transcripts, allowing doctors to monitor disease burden over time.

Furthermore, the BCR-ABL by PCR Quantitative Test plays a crucial role in evaluating the effectiveness of tyrosine kinase inhibitor (TKI) therapy, such as imatinib, dasatinib, nilotinib, bosutinib, or ponatinib. Regular monitoring helps determine whether treatment is working, detect minimal residual disease (MRD), identify early signs of treatment resistance or disease relapse, and guide decisions regarding therapy adjustments.

The test is often performed alongside Complete Blood Count (CBC), Bone Marrow Examination, Cytogenetic Analysis, Fluorescence In Situ Hybridization (FISH), and other molecular tests to provide a comprehensive assessment of leukemia.

BCR-ABL BY PCR QUANTITATIVE Test is Recommended for Individuals:

• Individuals suspected of having Chronic Myeloid Leukemia (CML).
• Patients diagnosed with Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
• Individuals undergoing treatment with tyrosine kinase inhibitors (TKIs).
• Patients requiring monitoring of treatment response in CML.
• Individuals being evaluated for minimal residual disease (MRD).
• Patients with suspected disease relapse or treatment resistance.
• Individuals advised by their hematologist or oncologist to undergo BCR-ABL molecular testing.

FAQs

1. What is the BCR-ABL by PCR Quantitative Test used for?

The BCR-ABL by PCR Quantitative Test measures the amount of the BCR-ABL fusion gene in the blood or bone marrow. It is primarily used to diagnose Chronic Myeloid Leukemia (CML), monitor treatment response, detect minimal residual disease, and identify early signs of relapse.

2. Do I need to fast before the BCR-ABL by PCR Quantitative Test?

No. Fasting is generally not required for this test. However, always follow any preparation instructions provided by your healthcare provider before sample collection.

3. What does a positive BCR-ABL Quantitative result mean?

A positive result indicates the presence of the BCR-ABL fusion gene, which is commonly associated with Chronic Myeloid Leukemia (CML) and some cases of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). The measured transcript level helps your doctor assess disease burden, monitor treatment effectiveness, and determine whether additional treatment or follow-up is required. Regular testing is often recommended to track response over time.